Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.

Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.
复制标题

非小细胞肺癌治疗:深入了解多靶点小分子生长因子受体抑制剂

DOI:
10.1155/2013/964743
复制
发表时间:
2013
影响因子:
--
通讯作者:
Liu J
Liu J
中科院分区:
生物学3区
文献类型:
--
作者:
Roy M;Luo YH;Ye M;Liu J

文献摘要

参考文献

被引文献

相似文献

迄今为止,肺癌是全球癌症相关死亡的主要原因,其中非小细胞肺癌(NSCLC)约占85%。考虑到手术、放疗、铂类双药化疗的副作用以及癌细胞生长自给自足的特点,针对生长因子受体(GFR)的药物已被发现用于治疗非小细胞肺癌(NSCLC)。正如预期的那样,这些药物提供了更大的益处。为了提高此类生长因子受体酪氨酸激酶抑制剂 (RTKI) 的功效,GFR 信号通路的共同抑制以及抑制剂与放疗或化疗的组合引起了人们的广泛关注。尽管有关单药 RTKI 或其组合策略的临床试验表明它们可以增强抗癌效力,但它们并非没有副作用,有时甚至比化疗更致命。尽管如此,通过进一步的研究和深入研究癌症疗法,RTKI 的希望可能会被证明是正确的。
To date, lung cancer is the leading cause of cancer-related death worldwide, among which nonsmall cell lung cancer (NSCLC) comprises about 85%. Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC. As expected, these drugs provide a greater benefit. To increase the efficacy of such growth factor receptor tyrosine kinase inhibitors (RTKIs), coinhibition of GFR signaling pathways and combination of inhibitors along with radiation or chemotherapy have drew intense insight. Although clinical trials about single-agent RTKIs or their combination strategies suggest their increase potency against cancer, they are not beyond adverse effects, and sometimes the effects are more deadly than chemotherapy. Nevertheless the hope for RTKIs may be proved true by further researches and digging deep into cancer therapeutics.
DOI: 10.1200/jco.2003.12.046
发表时间: 2003-08-15
影响因子: 45.3
作者:
Fossella, F;Pereira, JR;Belani, CP
通讯作者: Belani, CP
DOI: 10.1038/nrd2792
发表时间: 2009-03
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
通讯作者: --
DOI: 10.1200/jco.2010.29.5717
发表时间: 2011-03-01
影响因子: 45.3
作者:
de Boer, Richard H.;Arrieta, Oscar;Vansteenkiste, Johan F.
通讯作者: Vansteenkiste, Johan F.
DOI: 10.1016/j.canlet.2011.02.018
发表时间: 2011-05-28
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Charpidou, Andriani;Gkiozos, Ioannis;Syrigos, Kostas N.
通讯作者: Syrigos, Kostas N.